| Literature DB >> 34458863 |
Cynthia J Grondin1, Allan Peter Davis1, Jolene A Wiegers1, Thomas C Wiegers1, Daniela Sciaky1, Robin J Johnson1, Carolyn J Mattingly1,2.
Abstract
There is a critical need to understand the health risks associated with vaping e-cigarettes, which has reached epidemic levels among teens. Juul is currently the most popular type of e-cigarette on the market. Using the Comparative Toxicogenomics Database (CTD; http://ctdbase.org), a public resource that integrates chemical, gene, phenotype and disease data, we aimed to analyze the potential molecular mechanisms of eight chemicals detected in the aerosols generated by heating Juul e-cigarette pods: nicotine, acetaldehyde, formaldehyde, free radicals, crotonaldehyde, acetone, pyruvaldehyde, and particulate matter. Curated content in CTD, including chemical-gene, chemical-phenotype, and chemical-disease interactions, as well as associated phenotypes and pathway enrichment, were analyzed to help identify potential molecular mechanisms and diseases associated with vaping. Nicotine shows the most direct disease associations of these chemicals, followed by particulate matter and formaldehyde. Together, these chemicals show a direct marker or mechanistic relationship with 400 unique diseases in CTD, particularly in the categories of cardiovascular diseases, nervous system diseases, respiratory tract diseases, cancers, and mental disorders. We chose three respiratory tract diseases to investigate further, and found that in addition to cellular processes of apoptosis and cell proliferation, prioritized phenotypes underlying Juul-associated respiratory tract disease outcomes include response to oxidative stress, inflammatory response, and several cell signaling pathways (p38MAPK, NIK/NFkappaB, calcium-mediated).Entities:
Keywords: A, acetaldehyde; AC, acetone; C, crotonaldehyde; CGPD, chemical-gene-phenotype-disease; COPD, chronic obstructive pulmonary disease; CTD, Comparative Toxicogenomics Database; Cr, chromium; Database; E-cigarettes; Environmental exposure; F, formaldehyde; FR, free radicals; Juul; M, marker/mechanism relationship; MIE, molecular initiating event; MOA, mode-of-action; Mn, manganese; N, nicotine; NAFFCAPP, nicotine, acetaldehyde, formaldehyde, free radicals, crotonaldehyde, acetone, pyruvaldehyde, and particulate matter chemical mixture; NAFP, nicotine, acetaldehyde, formaldehyde, particulate matter chemical mixture; Ni, nickel; P, pyruvaldehyde; PM, particulate matter; Pb, lead; ROS, reactive oxygen species; Respiratory disease; Vaping; Zn, zinc; nAChR, nicotinic acetylcholine receptor
Year: 2021 PMID: 34458863 PMCID: PMC8379377 DOI: 10.1016/j.crtox.2021.08.001
Source DB: PubMed Journal: Curr Res Toxicol ISSN: 2666-027X
Concentrations of Chemicals in Juul Emissions.
| mean per 15 puffs ( | range per puff ( | |
|---|---|---|
| Nicotine, mg | 2.07 | 0.154 – 0.188 |
| Acetaldehyde, μg | 6.05 | not detected |
| Formaldehyde, μg | 0.56 | 0.12 – 0.26 |
| Free Radicals, pmol | not assessed | 5.47 – 6.13 |
| Crotonaldehyde, μg | 0.85 | not assessed |
| Acetone, μg | 24.9 | 0.17 – 0.22 |
| Pyruvaldehyde, μg | 0.95 | not assessed |
| Particulate Matter, mg | 38.9 | not assessed |
Fig. 1Curated Disease Associations to Chemicals in Juul Aerosols: nicotine (N), particulate matter (PM), formaldehyde (F), free radicals (FR), acetaldehyde (A), pyruvaldehyde (P), acetone (AC), crotonaldehyde (C). (A) The top five categories of diseases with direct relationships to chemicals in Juul aerosols are shown, detailing the number of curated relationships in these categories and distribution by chemical. (B) Numbers of direct marker/mechanistic relationships in all disease categories attributed to each chemical constituent in Juul aerosols.
Fig. 2Methodology to determine Juul-Affected Phenotypes in Respiratory Tract Disease Outcomes. The four Juul aerosol chemicals: nicotine, acetaldehyde, formaldehyde, and particulate matter (NAFP) show marker or mechanistic associations with pulmonary fibrosis, asthma, and lung neoplasms, which are independently supported by inferred relationships via 295 genes that interact with one or more Juul aerosol chemicals, and are independently curated to one or more of the three diseases. As well, the four chemicals directly modulate 552 phenotypes, while the 295 genes are independently annotated to 940 phenotypes. There were 248 phenotypes common to both sets. Furthermore, chemical-gene-phenotype-disease (CGPD) tetramers were computationally generated among the four NAFP chemicals and pulmonary fibrosis, asthma, and lung neoplasms, resulting in 112 shared phenotypes among the three sets of CGPDs. Comparison between the two sets of phenotypes reveal an intersection of 81 phenotypes, of which 65 are annotated to respiratory system, and are associated with 197 genes. These genes represent potential molecular initiating events in the mode-of-action of Juul chemicals on respiratory outcomes.
Fig. 3The top 20 most common prioritized phenotypes for Juul aerosol chemicals associated with pulmonary fibrosis, asthma and lung neoplasms. CGPD-tetramers were computationally generated for four chemicals in Juul aerosols (nicotine, formaldehyde, acetaldehyde, and particulate matter), interacting genes, intermediate phenotypes, and three respiratory tract diseases (pulmonary fibrosis, asthma and lung neoplasms). A total of 65 phenotypes were prioritized as shared among the CGPD-tetramers for the three target respiratory diseases, and annotated to the specific chemicals, genes in the inference network, and respiratory system, and the 20 most frequent phenotypes are presented as number of CGPD-tetramers per phenotype for each disease.
Fig. 4Predictive mechanistic pathways that relate Juul aerosol chemicals to representative respiratory outcomes, generated by integrating CTD content. Chemical-gene interactions between nicotine, acetaldehyde, formaldehyde and particulate matter and 197 genes represent potential molecular initiating events (MIE) that link the chemical toxicants to pulmonary fibrosis, asthma and lung neoplasms, and are represented by 26 genes that interact with all four of the chemicals. Nineteen phenotypes that are directly modulated by these chemicals and are annotated to genes they interact with represent potential intermediate steps along predictive mechanistic pathways, and align with intracellular, cellular, and system processes. All of the phenotypes were prioritized as key contributors to the pathways via four types of supporting evidence: 1) curated chemical-phenotype interaction 2) curated gene-phenotype annotation 3) imported gene-GO annotation 4) computational generation of chemical-gene-phenotype-disease tetramers. Phenotypes shown in bold italic were among the 20 most frequent phenotypes in computationally generated CGPD tetramers. Numbers in parentheses represent the total number of genes of the 197 potential MIEs associated with each phenotype, with associations designated by solid black lines. Curved gray arrows indicate phenotypes that are interrelated via shared genes.
Significantly Enriched Pathways of NAFFCAPP-interacting Genes.
| Enriched Pathway | Pathway ID | Total number unique NAFFCAPP genes annotated to pathway | Particulate Matter | Formaldehyde | Nicotine | Free Radicals-Reactive Oxygen Species | Acetaldehyde | Pyruvaldehyde | Crotonaldehyde | Acetone |
|---|---|---|---|---|---|---|---|---|---|---|
| Immune System | REACT:R-HSA-168256 | 1,084 | 722 | 541 | 276 | 144 | 62 | 41 | 43 | 7 |
| Metabolism | REACT:R-HSA-1430728 | 1,071 | 680 | 464 | 209 | 89 | 48 | 22 | 0 | 0 |
| Signal Transduction | REACT:R-HSA-162582 | 1,101 | 697 | 511 | 300 | 126 | 76 | 31 | 45 | 0 |
| Innate Immune System | REACT:R-HSA-168249 | 681 | 468 | 304 | 176 | 105 | 40 | 29 | 23 | 0 |
| Gene Expression | REACT:R-HSA-74160 | 837 | 429 | 467 | 144 | 53 | 29 | 0 | 0 | 0 |
| Metabolism of proteins | REACT:R-HSA-392499 | 735 | 456 | 334 | 143 | 56 | 24 | 0 | 0 | 0 |
| Cytokine Signaling in Immune system | REACT:R-HSA-1280215 | 442 | 308 | 235 | 149 | 80 | 40 | 26 | 30 | 6 |
| Metabolic pathways | KEGG:hsa01100 | 605 | 362 | 281 | 111 | 47 | 32 | 0 | 0 | 0 |
| Disease | REACT:R-HSA-1643685 | 458 | 323 | 198 | 123 | 58 | 32 | 14 | 0 | 0 |
| Signaling by Interleukins | REACT:R-HSA-449147 | 325 | 245 | 168 | 124 | 68 | 35 | 24 | 26 | 6 |